Fight MS with HKMSS!

Contact us at webmaster@hkmss.org

Scientific Symposium

HKMSS 11th Annual Scientific Meeting

15 Oct 2022

13:00 - 17:00

Webinar

Speaker(s)

Dr. Eppie Yiu

University of Melbourne
Australia

Dr. Daniel O'Neill

Liverpool Hospital
Australia

Prof. Noriko Isobe

Kyushu University
Japan

Dr. Stephen Cheng

HKMSS Council

Ms Sharon Chiu

Pamela Youde Nethersole Eastern Hospital
Hong Kong

Prof. Wei Qiu

Sun Yat-sen University
China

On 15 October 2022, the HKMSS held its 11th Annual Scientific Meeting as a virtual webinar. Despite being a half day event, we had to honour to learn from international, regional and local experts.

Paediatric multiple sclerosis and related disorders

Dr. Eppie Yiu from the University of Melbourne, Australia, began with her talk ‘Paediatric multiple sclerosis and related disorders’, where she highlighted the differences between childhood and adult MS.

MS pathology: new insights and potential implications for treatment. The role of cladribine in disease treatment and control

Dr. Daniel O’Neill from Liver Hospital, Australia, then enlightened us on ‘MS pathology: new insights and potential implications for treatment’, where he discussed the role of cladribine in disease treatment and control.

Optimising the use of DMTs for long-term benefit of MS treatment

Prof. Noriko Isobe from Kyushu University, Japan, next shared her expertise on ‘Optimising the use of DMTs for long-term benefit of MS treatment’, during which she gave a special focus on extended interval use of Natalizumab.

Multiple sclerosis functional assessment

Our Vice President, Dr. Stephen Cheng, was then joined by Ms Sharon Chiu, an Occupational Therapist working at PYNEH, and talked about ‘Multiple sclerosis functional assessment’, exploring tools other than the EDSS.

Clinical experience on B-cell therapy in Multiple Sclerosis: Role of Ofatumumab and differentiating it from Rituximab

In the last talk of the symposium, Prof. Wei Qiu from Sun Yat-sen University, China, shared on his ‘Clinical experience on B-cell therapy in Multiple Sclerosis’, where he focused on the role of Ofatumumab and how it differentiates from Rituximab.

We would like to thank all our speakers and chairpersons for making this a successful event!